Bio-Techne (TECH) Liabilities and Shareholders Equity (2009 - 2026)
Bio-Techne (TECH) posted quarterly Liabilities and Shareholders Equity of $2.6 billion for Q1 2026, down 3.54% year-over-year from $2.6 billion in Q1 2025, and up 1.11% quarter-over-quarter from $2.5 billion in Q4 2025.
Bio-Techne (TECH) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Bio-Techne's Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 3.54% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $10.2 billion (down 5.55% YoY), while the FY2025 annual figure was $2.6 billion, down 5.4% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $2.6 billion, up from $2.5 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $2.8 billion in Q3 2023, with the low at $2.3 billion in Q2 2022.
- The 5-year median for Liabilities and Shareholders Equity is $2.6 billion (2023), against an average of $2.6 billion.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity advanced 17.21% in 2023, then declined 7.67% in 2025.
- Bio-Techne's Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then advanced by 15.54% to $2.7 billion in 2023, then declined by 2.21% to $2.7 billion in 2024, then fell by 5.53% to $2.5 billion in 2025, then increased by 1.11% to $2.6 billion in 2026.
- Business Quant data shows TECH's Liabilities and Shareholders Equity at $2.6 billion in Q1 2026, $2.5 billion in Q4 2025, and $2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.55 Bn |
| Dec 31, 2025 | 2.52 Bn |
| Sep 30, 2025 | 2.53 Bn |
| Jun 30, 2025 | 2.56 Bn |
| Mar 31, 2025 | 2.64 Bn |
| Dec 31, 2024 | 2.67 Bn |
| Sep 30, 2024 | 2.74 Bn |
| Jun 30, 2024 | 2.70 Bn |
| Mar 31, 2024 | 2.72 Bn |
| Dec 31, 2023 | 2.73 Bn |
| Sep 30, 2023 | 2.76 Bn |
| Jun 30, 2023 | 2.64 Bn |
| Mar 31, 2023 | 2.60 Bn |
| Dec 31, 2022 | 2.36 Bn |
| Sep 30, 2022 | 2.35 Bn |
| Jun 30, 2022 | 2.29 Bn |
| Mar 31, 2022 | 2.30 Bn |
| Dec 31, 2021 | 2.30 Bn |
| Sep 30, 2021 | 2.27 Bn |
| Jun 30, 2021 | 2.26 Bn |